Craft

American CryoStem

Stock Price

$0

2024-04-10

Market Capitalization

$4.4 K

2024-04-10

Revenue

$20.6 K

FY, 2021

American CryoStem Summary

Company Summary

Overview
American CryoStem Corporation develops, markets, and licenses patented adipose tissue-based cellular technologies and related proprietary services. It focuses on clinical processing, commercial bio-banking, and application development for adipose tissue and autologous adipose-derived regenerative cells. The company's products include CELLECT validated collection, transportation, and storage system, which is a clinical solution for physicians to collect and deliver tissue samples; ATGRAFT adipose tissue storage service, a clinical fat storage solution that enables physicians to provide their patients with various tissue/cell storage options; and ATCELL adipose derived stem cells. It also offers ACSelerat cell culture media products for growing human stromal cells. In addition, the company, through its ACS Laboratories division, manufactures and sells patented and patent pending cellular, cell culture, processing, and testing products to professional, institutional, and commercial clients; and provides professional services.
Type
Public
Status
Active
Founded
2008
HQ
Eatontown, NJ, US | view all locations
Website
http://www.americancryostem.com/
Cybersecurity rating
Sectors

Key People

  • John Arnone, Chairman & Chief Executive Officer

    • Anthony Dudzinski, COO

      • Ruth Goldman, Vice President, Laboratory Director

        LocationsView all

        1 location detected

        • Eatontown, NJ HQ

          United States

          1 Meridian Rd

        American CryoStem Financials

        Summary Financials

        Revenue (Q3, 2022)
        $42.6K
        Gross profit (Q3, 2022)
        $37.8K
        Net income (Q3, 2022)
        ($401.7K)
        Cash (Q3, 2022)
        $2.8K
        EBIT (Q3, 2022)
        ($376.8K)
        Enterprise value
        $849.6K

        Footer menu